Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...
Hosted on MSN2mon
Regeneron Culls Losses After High-Dose Eylea Sales DisappointRegeneron stock recovered and closed higher Monday after the drugmaker preannounced light sales of a high-dose version of its blockbuster eye drug, Eylea. Please watch the video at Investors.com ...
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...
In 2024, sales of Eylea (low dose and HD combined ... Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled ...
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback